Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 6/20 | 0.49 |
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | FABP3 | P05413 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4552166 | 0.81 | FABP4 (0.64) | FABP4FABP5MEN1KMT2AMAOA | |
| SCHEMBL4552481 | 0.81 | FABP4 (0.68) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL10090172 | 0.81 | ALDH1A1 (0.64) | FABP4FABP5MEN1KMT2AMAOA | |
| SCHEMBL29941758 | 0.81 | ALDH1A1 (0.64) | FABP4FABP5MEN1KMT2AMAOA | |
| SCHEMBL4730270 | 0.79 | SMN1; SMN2 (0.56) | FABP4FABP5MEN1KMT2ACYP1A2 | |
| SCHEMBL10063551 | 0.79 | MAOA (0.69) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL6338101 | 0.79 | MAOA (0.69) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL5181736 | 0.79 | MAOA (0.69) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL5658338 | 0.79 | MAOA (0.69) | FABP4FABP5MAOAMAOBACHE | |
| SCHEMBL16900269 | 0.77 | FABP4 (0.47) | FABP4FABP5MEN1KMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292249-A1 | MANUFACTURE OF RIMCAZOLE | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-18 | — | — | US | disclosed |
| US-20100292249-A1 | MANUFACTURE OF RIMCAZOLE | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-18 | — | — | US | disclosed |
| WO-2008040950-A1 | MANUFACTURE OF RIMCAZOLE | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292249-A1 | MANUFACTURE OF RIMCAZOLE | P2RX5, CYP3A5, ADRA2C | FABP4 3133/4885FABP5 2341/4885MEN1 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.